At the recent Precision Medicine Leaders Summit in San Diego, five innovators in the field of precision medicine convened onstage to discuss what it will take to capitalize on this historic convergence of need, knowledge and technology.
The panel agreed that widespread adoption of precision medicine will require well-timed and strategic collaborations between the clinical community, academia, biopharma, industry and patients. But how close are we? Do we really understand enough about a patient’s unique and highly complex molecular profile? Are we prepared to manage and analyze the zettabytes of data that are required to make precision medicine insights actionable and scalable?
The answer, many believe, will depend on the rapid and rational integration of multi-omic data. This is precisely what the distinguished panelists representing Tom Conrads at Inova Schar Cancer Institute, NantOmics, the National Institutes of Health, Liquid Biosciences and the Peter MacCallum Cancer Centre discussed during the Summit panel.
To watch the full version of the panel, please click here.